Absence of a functional NADPH oxidase predisposes chronic granulomatous disease (CGD) patients to infection, and also to unexplained, exaggerated inflammation. The impaired recognition and removal (efferocytosis) of apoptotic neutrophils by CGD macrophages may contribute to this effect. We hypothesized that PPARγ activation during CGD inflammation is deficient, leading to altered macrophage programming and decreased efferocytosis, and that PPARγ agonism would enhance resolution. Utilizing the 
Introduction
While prophylactic administration of antibiotic and antifungal agents reduce the occurrence of infections in chronic granulomatous disease (CGD) patients, they suffer from exaggerated, often sterile inflammation (e.g. poor wound healing, obstructing granuloma, and colitis) and autoimmunity, the mechanisms for which are not fully understood [1] [2] [3] [4] . Among the various inflammatory mechanisms described in CGD, improper or deficient signaling by activated and apoptosing neutrophils has been proposed [5] [6] [7] . Impaired degradation of pro-inflammatory mediators [8] [9] [10] , deficient upregulation of adenosine and cAMP production 11 , and tryptophan catabolism 12 are also described. Finally, the impaired recognition and clearance (efferocytosis) of dying neutrophils by CGD macrophages is hypothesized 11, 13, 14 . Proper recognition and clearance of apoptotic cells by macrophages is actively anti-inflammatory and required for restoration of tissue function [15] [16] [17] . Conversely, dying neutrophils, if not recognized and cleared, release injurious intracellular constituents, which further spur inflammation and autoimmunity 7, 18, 19 .
The ability of macrophages to clear dying cells needed for resolving inflammation is dependent on their "programming." Macrophage programming has been traditionally termed "classical" or M1 when induced with LPS+IFNγ and associated with Th1 cytokines, and "alternative" or M2 when induced by IL-4+IL-10, and associated with Th2 cytokines 20, 21 . While this dichotomy is clearly oversimplified 22 , M2 programming is required for efferocytic capability and has been shown to be dependent on macrophagespecific PPARγ [23] [24] [25] . We recently demonstrated that macrophages from the naïve peritoneum of gp91 phox-/-mice (a model of X-linked CGD) were classically activated, had low levels of PPARγ expression, and were poorly programmed to recognize and clear normal (non-CGD) apoptotic cells compared to wild type (WT) macrophages 13 . These observations prompted us to hypothesize that deficient PPARγ signaling, given its various roles in controlling inflammation 26, 27 , might underlie the heightened inflammation characteristic of CGD. Specifically, deficient PPARγ signaling might lead to impaired clearance of dying neutrophils and loss of suppression of inflammatory mediator production by CGD macrophages. Finally, we hypothesized to the extent that
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From deficient PPARγ signaling was key to exaggerated inflammation in this model, its restoration with a PPARγ agonist would normalize the course of CGD inflammation.
Using a model of acute peritonitis, prolonged inflammation in CGD mice was associated with delayed macrophage PPARγ signaling relative to that of WT mice.
Accumulation of apoptotic neutrophils and lower levels of efferocytosis by CGD macrophages in vivo demonstrated impaired apoptotic cell removal in this disorder. As hypothesized, restoration of PPARγ signaling via oral administration of pioglitazone, a potent PPARγ agonist, significantly shortened the course of peritonitis in CGD mice, and the data supported a significant role for enhanced efferocytosis in this effect. Taken together, the data support that PPARγ may be key to regulating inflammation in CGD and point to restoration of PPARγ signaling as a potential therapeutic target in this disorder.
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Materials and Methods

Animals. Male C57BL/6 and X-CGD (gp91
phox-/-) mice were purchased from Jackson Laboratories (Bar Harbor, ME) or bred in a colony housed at National Jewish Health (Denver, Colorado). All animals received care in accordance with the Institutional Animal Care and Use Committee and were maintained on food and water ad libitum.
Mice between the ages of 8 and 16 weeks were age and gender matched for all experiments. Mice were euthanized using CO 2 inhalation. 
Results
PPARγ expression and activation are deficient in CGD macrophages during acute inflammation.
In our earlier investigation, we showed that PPARγ protein levels were significantly lower in resident macrophages from the naïve peritoneum of CGD compared to WT mice 13 . We therefore asked whether PPARγ levels were also deficient in CGD mice during acute inflammation. 
Lower macrophage PPARγ expression and activation are associated with enhanced inflammation in CGD mice.
Given that PPARγ is known to inhibit AP-1, SP1 and NF-κB driven proinflammatory cytokine transcription 24, 26, 34 , it was hypothesized that elevated levels of mediators might reflect delayed or deficient acquisition of PPARγ expression and activity in CGD mice. Pro-inflammatory mediators, directly or indirectly associated with leukocyte recruitment, were measured in peritoneal lavage. Baseline levels of IL-6 and TNFα were found to be elevated in CGD (vs. WT) mice, and following zymosan installation, IL-6, TNFα and KC levels were higher and their elevation prolonged in CGD mice (Fig. 2 ). In keeping with these findings, neutrophil numbers during peritonitis were increased and sustained in CGD mice (vs. WT) (Fig. 3A) as shown in previous reports of exaggerated neutrophilic inflammation in this model 5, 9, 11 while the numbers of other inflammatory cells were very similar (Fig. 1A, Fig. S2 ). Neutrophilia was ultimately self-limited in both WT and CGD mice, and resolution indices described by Bannenberg et al. 35 were determined (Table 1) : the maximal numbers of neutrophils (ψ max ) accumulating in the peritoneum and the time for resolution of neutrophilia (T 50 , and R i ) were greater in CGD compared to WT mice while the time (T max ) to ψ max was not different. Additionally, the time to achieve equal numbers of neutrophils to macrophages (I pmn=mono ) was longer in CGD mice (Table 1) . Thus, both inflammatory mediators and neutrophilic inflammation were significantly exaggerated in CGD mice and associated with delayed acquisition of PPARγ expression and activity.
Aside from altered macrophage programming in CGD, increased neutrophil longevity has also been hypothesized to contribute to exaggerated neutrophilia in CGD.
Defects and/or delays in the apoptosis of both human and murine CGD neutrophils have been described, though mostly following in vitro culture [5] [6] [7] . Thus, we investigated neutrophils for evidence of apoptosis immediately after lavage from inflamed peritonea.
PS exposure, which has been demonstrated during both neutrophil activation and apoptosis, was assessed by binding of Factor Va (data not shown) and annexin V (Fig.   3B ). Over the course of peritonitis, 7-10% of neutrophils exposed PS regardless of genotype or time point and no differences were observed between CGD and WT ( Fig.   3B ), confirming a recent report by Rajakariar et al. 11 . Similarly, extrapolation of data demonstrated that the absolute numbers of PS exposing neutrophils were similar for CGD as compared to WT mice at 16 and 24 h (at 48 h, very few neutrophils remained in peritonea of WT mice) (Fig. 3C) . Because of our earlier demonstration that activated neutrophils expose PS 28,5 (and may thereby initiate their removal by efferocytosis), we also evaluated neutrophil apoptosis by nuclear morphology. Significantly, using this criterion, the number of apoptotic neutrophils at each time point was higher in CGD than WT mice, as was the ratio of apoptotic neutrophils per macrophage present in the peritonea (Fig. 3D ).
Given that apoptotic cells are rarely seen in tissues in the absence of defects in clearance 15, 19, 36, 37 , these data suggested that impaired clearance of neutrophils contributed to their accumulation during CGD inflammation. Accordingly, macrophages lavaged from peritonea were examined microscopically for evidence of in vivo efferocytosis of apoptotic cells. Detectible efferocytosis was found to be significantly lower for CGD compared to WT macrophages (Fig. 3E) 4A ). Notably, PPARγ agonism has been shown to provide positive feedback for its own expression in other settings 39 (and see below). In CGD mice, the percent of resident peritoneal macrophages positive for PPARγ was also enhanced (Fig. S3, Baseline) . (Fig. 4A) nearly normalizing them to levels seen in WT cells. In WT mice, pioglitazone treatment did not further enhance timedependent macrophage PPARγ expression during peritonitis (Fig. 4A and S3A ). As before, the only cells in peritonea of either genotype that expressed PPARγ were F4/80 positive macrophages.
Following instillation of zymosan, pioglitazone treatment of CGD mice increased the
As measures of PPARγ activity, macrophage surface expression of the induced markers CD36 and MMR was investigated. On CGD macrophages, pioglitazone treatment enhanced surface expression of these markers and the percent of macrophages staining positive, both at baseline and during peritonitis ( Fig. 4B and C, Fig. S3B and C) .
Furthermore, their increased expression was reflective of levels of PPARγ expression:
where pioglitazone enhanced levels of PPARγ expression in CGD macrophages, surface levels of these proteins were also enhanced. For WT macrophages, pioglitazone treatment similarly enhanced levels of these markers ( Fig. 4B and C) PPARγ expression and activation were measured, the latter both directly (in nuclear extracts) and by assessment of expression of downstream targets. As shown in Fig. S4A , the expression of PPARγ in CGD macrophages was diminished compared to WT macrophages mirroring the levels in freshly lavaged macrophages (Fig. 1B) . Baseline PPARγ activity was also reduced in CGD macrophages relative to WT (Fig. S4B) .
Importantly, treatment of cultured CGD macrophages with pioglitazone enhanced PPARγ expression (Fig. S4A) , its activity (Fig. S4B) , and downstream markers (Fig. S4 C, D) to levels at or above those observed in vehicle-treated WT macrophages. The (Fig. S4A-D) . In WT macrophages, ex vivo pioglitazone treatment enhanced PPARγ activity as assessed by both direct and downstream measures (Fig. S4B-D ) (while having no effect on its expression). Similarly, the antagonist diminished baseline and pioglitazone stimulated PPARγ activity and reduced the expression of the markers, but had no effect on the expression of PPARγ in WT macrophages (Fig. S4) .
Collectively, these data confirmed the in vivo findings and supported the hypothesis that PPARγ is deficient in CGD macrophages and that treatment with pioglitazone restored PPARγ activity and consequent macrophage programming in CGD mice.
Given these findings, it was hypothesized that restoration of PPARγ signaling would ameliorate neutrophilic inflammation in CGD mice. As shown in figure 5A , treatment of CGD mice with pioglitazone restored the time course of neutrophilia during peritonitis to that seen in vehicle-treated WT mice. Additionally, in WT mice, pioglitazone treatment diminished the course of neutrophilia. Analyses demonstrated that for CGD mice, the maximum numbers of neutrophils (ψ max ) was significantly reduced, and for both CGD and WT mice, resolution indices (T 50 , R i and I pmn=mono ) were shortened following treatment with pioglitazone compared to vehicle treatment (Table 2 ). Since the numbers of macrophages lavaged from peritonea were not altered in either of the treatment groups (data not shown), the experiments support a restoration of macrophage function rather than alteration of their numbers.
Notably, early accumulation of neutrophils during peritonitis (up to 6 h following zymosan instillation) was not affected by pioglitazone treatment in either CGD or WT mice (Fig. 5B) suggesting that PPARγ activation did not suppress early neutrophil recruitment in this model, but rather altered subsequent events. Along these lines, levels of pro-inflammatory cytokines associated with leukocyte recruitment (e.g. KC) were measured in lavage following pioglitazone treatment. At 3 h following zymosan instillation, levels of these mediators were not altered, regardless of genotype or treatment (Fig. 5C , data shown for CGD mice only and compare to Fig. 2 (Fig. 5C ) and comparable to untreated WT mice (compare to Fig. 2) . These data suggest that in CGD mice, deficient PPARγ mediated suppression of pro-inflammatory mediator production contributes to baseline inflammation and to the protracted course of neutrophilia.
PPARγ agonism enhances efferocytosis in CGD mice.
We hypothesized that restoration of PPARγ activation and consequent M2 programming would restore efferocytosis in CGD. As predicted, pioglitazone treatment normalized in vivo efferocytosis by CGD macrophages during peritonitis to levels seen in WT macrophages (Fig. 6A) . Reflective of heightened clearance, the ratio of apoptotic neutrophils to macrophages during peritonitis was also reduced with pioglitazone treatment in CGD mice compared to vehicle treatment (Fig. 6B) . Finally, in vivo capacity for efferocytosis was formally tested by challenge with carboxylated beads injected into peritonea. Pioglitazone treatment significantly enhanced bead uptake by CGD macrophages at baseline compared to vehicle, and importantly, normalized efferocytosis to levels seen in WT mice over the course of inflammation (Fig. 6C) . In WT mice, pioglitazone treatment did not enhance in vivo macrophage efferocytosis and had no detectible effect on accumulation of apoptotic neutrophils ( Fig. 6A and B) . Finally, while pioglitazone treatment did not significantly increase the percent of WT macrophages that took up beads (Fig. 6C) , bead fluorescence was higher in WT macrophages at all time points suggesting that PPARγ agonism increased the uptake of targets per macrophage (data not shown).
These effects of pioglitazone treatment on efferocytosis were further investigated ex vivo. Baseline differences in efferocytosis between the genotypes were also observed in inflammatory macrophages lavaged from peritonea and cultured overnight (vehicle For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From treated) (Fig. S5A) . Ex vivo treatment of macrophages of both genotypes with pioglitazone (vs. vehicle) resulted in enhanced efferocytosis. The PPARγ antagonist inhibited these responses to pioglitazone, and reduced baseline levels of efferocytosis by vehicle treated WT macrophages to levels resembling CGD (Fig. S5A) . Importantly, these data mirrored PPARγ activity and expression investigated for both genotypes (Fig.   S4) , and further supported the hypothesis that restoration of macrophage programming restores efferocytosis of CGD macrophages in a PPARγ dependent manner. Since the pro-resolution cytokines IL-10 and TGFβ have been shown to be associated with macrophage recognition and clearance of apoptotic cells 15, 16, 17 , these cytokines were determined in the culture supernatants. Following co-culture with apoptotic cells for 1h, unengulfed cells were washed out and the macrophages incubated for an additional 18 h.
Associated with their deficient efferocytosis, vehicle-treated CGD inflammatory macrophages produced less IL-10 and TGFβ than WT following co-culture with apoptotic cells (Fig. S5) . Ex vivo pioglitazone treatment in addition to restoring efferocytosis in CGD macrophages, restored production of these cytokines made in response to apoptotic cells to levels seen in vehicle treated WT macrophages. Treatment with the PPARγ antagonist reversed these effects of pioglitazone on CGD macrophages, and had suppressive effects on WT macrophage cytokine production both at baseline and following pioglitazone treatment (Fig. S5 B and C) . Collectively, these data suggest that PPARγ activation of CGD macrophages by pioglitazone normalizes their ability to respond appropriately to apoptotic cells with the production of anti-inflammatory cytokines and to clear the apoptotic cells, both key for resolving inflammation.
Pioglitazone enhances resolution of neutrophilia in CGD mice via macrophage programming and efferocytosis even when administered after onset of inflammation.
The in vivo experiments above demonstrated that prophylactic PPARγ agonism ameliorated baseline differences in macrophage programming and cytokines as well as suppressed exaggerated inflammatory responses in CGD animals (Fig. 4, 5C and 6 ).
Thus, it was important to further sort out the effects of PPARγ agonism on the baseline milieu vs. its alteration of events in the propagation of inflammation or its resolution in CGD mice. Additionally, these experiments would indicate whether PPARγ activation might be beneficial in the treatment of ongoing inflammation. Therefore, we asked whether pioglitazone treatment begun after zymosan instillation would alter the course of subsequent inflammation. Mice were treated with a single oral dose of pioglitazone or vehicle 24 h post zymosan injection and peritoneal lavage was performed 24 h later (48 h post zymosan). As such, pioglitazone treatment was begun well after acute inflammatory mediators had subsided (Fig. 2) and after maximal neutrophil numbers had been achieved in both genotypes, and coincident with resolving peritonitis in WT. Analysis of peritoneal cells from CGD mice at 48 h demonstrated that neutrophil numbers were significantly reduced by delayed pioglitazone treatment compared to vehicle (Fig. 7A) . No effect on neutrophilia of WT mice was observed, though peritonitis was largely resolved in these mice at this point even without treatment. Significantly, the ratio of apoptotic neutrophils to macrophages was lower in CGD peritonitis following pioglitazone treatment (Fig. 7B) and was associated with enhanced in vivo efferocytosis by macrophages approximating levels seen in WT (Fig. 7C) . Paralleling the effect on efferocytosis, the levels of TGFβ as well as IL-10 in peritoneal lavage were increased following pioglitazone in the CGD mice, and also WT mice (Fig. 7D) . In addition, delayed pioglitazone treatment of CGD mice resulted in enhanced PPARγ expression and activity as indicated by an increase in CD36 and MMR staining (Fig. 7E) , though delayed treatment did not completely restore levels to those seen in WT mice or following prophylactic/concurrent treatment in CGD.
These observations during delayed treatment collectively support the hypothesis that PPARγ agonism significantly attenuates neutrophilic inflammation in CGD via normalization of inflammatory macrophage programming and efferocytosis.
For
Discussion
PPARγ expression is markedly upregulated in macrophages during acute inflammation 27, 31 , and its activation plays various roles in resolution including suppression of inflammatory mediator production 24, 26, 34 and altering macrophage phenotype and functions [23] [24] [25] . (Fig. 5C ), nor early neutrophil recruitment (up to 6 h post zymosan) (Fig. 5B) were altered in CGD or WT mice. These early events were associated temporally with very low levels of PPARγ expression in F4/80 positive populations, characteristic of recruited blood monocytes from which inflammatory macrophages differentiate 31 . These macrophages were also functionally distinct in their impaired efferocytosis ( Fig. 1 and 3) , and given their low expression of PPARγ, would be predicted to be unresponsive to pioglitazone treatment. Only as macrophage PPARγ protein increased, were subsequent inflammatory events suppressed by pioglitazone treatment. Accordingly, the prolonged elevations of inflammatory mediators (Fig. 5C) and consequent neutrophil recruitment (Fig. 5A ) characteristic of CGD mice were reduced by PPARγ activation.
Though the effect of PPARγ activation may be mediated via its transrepression of pro-inflammatory mediator transcription 24, 26, 34 , we hypothesize an even more significant indirect effect via enhanced apoptotic cell recognition which then leads to the production of suppressive mediators such as IL-10 and TGFβ (Figs. S5, 7D ) 17, 43, 44 . Further, we hypothesized that efficient removal of dying neutrophils prevented disintegration and release of phlogistic intracellular constituents that prolong production of inflammatory mediators 7, 18 . PPARγ agonism normalized efferocytosis in CGD mice (Figs. 6A and C, 7C, S5A); enhanced uptake was demonstrated in vivo for bead mimics, and importantly, for CGD neutrophils which reportedly signal suboptimally for uptake [5] [6] [7] . Further insights are provided by the delayed administration model. Here, pioglitazone enhanced resolution of neutrophilia when administered after inflammatory mediators had subsided and maximal neutrophil accumulation was achieved. These data strongly support the hypothesis that impaired efferocytosis significantly contributes to CGD inflammation.
The mechanisms by which PPARγ activation mediate efferocytic capacity are to be further investigated, but likely involve ligand-dependent transactivation. Following ligand binding, PPARγ heterodimerizes with the retinoid X receptor or other nuclear receptors (e.g. LXR or glucocorticoid receptor), and with associated coactivators binds to PPAR-response elements in promoter regions altering transcription 26, 27 . PPARγ transactivation is known to upregulate proteins involved in both apoptotic cell recognition (e.g. CD36 and MMR) and digestion (e.g. ABCA1) 24, 32, 33, 45 .
Administration of PPARγ agonists in vivo significantly ameliorates arthritis, colitis, and atherosclerosis in animal models 27 , and these agents are currently in trial in humans with metabolic syndrome, obesity, end-stage renal disease, ulcerative colitis, rheumatoid arthritis, allergic asthma, and COPD (many of which are also associated with aberrant macrophage programming and impaired efferocytosis 46 ). Based on this preclinical model, PPARγ agonism may be effective in the treatment of CGD inflammation.
Notably, in this peritonitis model, pioglitazone was effective even when started after the induction of inflammation raising the possibility of intermittent, as needed therapy rather than prophylactic. Thiazolidinedione treatment is attractive in that these agents are not globally immunosuppressive like glucocorticoids currently used to suppress CGD inflammation, though to date, their use during active bacterial or fungal infections has not been investigated. Studies to investigate the prophylactic or delayed effect of pioglitazone administration (and after initiating treatment with antimicrobials) in CGD mice are underway. In this regard, it is relevant that PPARγ agonism has been reported to enhance phagocytosis of Candida 47 and Fc-mediated phagocytosis by macrophages 48 .
Gene therapy for restoration of the NADPH oxidase is clearly the ultimate goal in the treatment of CGD, though the precise means of accomplishing this safely and
effectively are yet to be established 49 . Importantly, transduction of even modest numbers of neutrophils is curative of immunodeficiency, and, may diminish inflammation as well 50 
